The Antiviral Properties of Cyclosporine. Focus on Coronavirus, Hepatitis C Virus, Influenza Virus, and Human Immunodeficiency Virus Infections
- Glowacka, Paulina
- Rudnicka, Lidia ORCID
- Warszawik-Hendzel, Olga
- Sikora, Mariusz ORCID
- Goldust, Mohamad
- Gajda, Patrycja
- Stochmal, Anna
- Blicharz, Leszek ORCID
- Rakowska, Adriana
- Olszewska, Malgorzata
- 2020-7-28
Published in:
- Biology. - MDPI AG. - 2020, vol. 9, no. 8, p. 192
English
This review updates current knowledge regarding the risk of viral infections, including COVID-19, in patients treated with cyclosporine. We also shortly refer to bacterial infections and parasitic infestations in patients treated with cyclosporin. Cyclosporine is an immunosuppressive drug, which is widely used in medicine, including in the treatment of autoimmune skin diseases in dermatology, rheumatology, ophthalmology and nephrology, and in organ transplantation. A usual concern associated with immunosuppressive treatment is the potential risk of infections. Interestingly, several data indicate a relatively low risk of infections, especially viral infections, in patients receiving cyclosporine. It was shown that cyclosporine exerts an inhibitory effect on the replication of some viruses, or may have a potentially beneficial effect on the disease course in infections. These include hepatitis C, influenza virus, rotavirus, human immunodeficiency virus and coronavirus infections. Available data indicate that cyclosporine may have a beneficial effect on COVID-19, which is caused by the coronavirus SARS-COV2.
- Language
-
- English
- Open access status
- gold
- Identifiers
-
- DOI 10.3390/biology9080192
- ISSN 2079-7737
- Persistent URL
- https://sonar.ch/global/documents/42181
Statistics
Document views: 6
File downloads:
- fulltext.pdf: 0